Gao X, Ning Y
Channing Laboratory (XG), Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts 02115, USA.
Drugs Today (Barc). 2011 Mar;47(3):215-22. doi: 10.1358/dot.2011.47.3.1519657.
Epidemiological studies have consistently shown that individuals with Parkinson's disease (PD) are less likely to develop nonmelanoma cancers and vice versa. In contrast, the co-occurrence of PD and melanoma has been reported in numerous studies. The exact mechanisms underlying the observed cancer-PD association are not clear. Different hypotheses have been put forward, including shared environmental/lifestyle factors (e.g., smoking and socioeconomic status) and common genetic components (e.g., parkinson protein 2 [PARK2], leucine-rich repeat kinase 2 [LRRK2], Parkinson disease [autosomal recessive, early onset] 7 [PARK7, DJ-1] and pigmentation genes). In the current review, we summarize recent findings to offer new insight into the pathogenesis of both conditions.
流行病学研究一直表明，帕金森病（PD）患者患非黑色素瘤癌症的可能性较小，反之亦然。相比之下，许多研究报告了PD与黑色素瘤的同时发生。观察到的癌症与PD关联背后的确切机制尚不清楚。已经提出了不同的假设，包括共同的环境/生活方式因素（如吸烟和社会经济地位）和共同的遗传成分（如帕金森蛋白2 [PARK2]、富含亮氨酸重复激酶2 [LRRK2]、帕金森病[常染色体隐性，早发性] 7 [PARK7，DJ-1]和色素沉着基因）。在本综述中，我们总结了最近的发现，以提供对这两种疾病发病机制的新见解。
